Get the Stockscreener App
19.99
4.88%
0.93
After Hours:
19.98
-0.010
-0.05%
Forte Biosciences Inc stock is traded at $19.99, with a volume of 180.27K.
It is up +4.88% in the last 24 hours and up +65.07% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$19.06
Open:
$19.49
24h Volume:
180.27K
Relative Volume:
1.76
Market Cap:
$250.41M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-19.22
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
+11.24%
1M Performance:
+65.07%
6M Performance:
+135.45%
1Y Performance:
+24.32%
1-Day Range:
$18.34
$20.00
1-Week Range:
$18.00
$21.99
52-Week Range:
$4.90
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
19.99 | 238.76M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences initiated with an Outperform at Evercore ISI - TipRanks
Evercore ISI initiates coverage on Forte Biosciences stock with Outperform rating - Investing.com
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - Enidnews.com
Forte Biosciences Inc. (FBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Forte Biosciences Inc a good long term investmentHead and Shoulders Patterns & Small Investment Big Gains - earlytimes.in
What analysts say about Forte Biosciences Inc stockVolume Spike Alerts & Affordable Market Trading - earlytimes.in
Why Forte Biosciences Inc. (37T) stock is a strong buy callQuarterly Earnings Report & Technical Pattern Recognition Alerts - newser.com
What analyst consensus implies for Forte Biosciences Inc. (37T) stockJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
What is Chardan Capital’s Estimate for FBRX FY2025 Earnings? - Defense World
Why Forte Biosciences Inc. (37T) stock appears on watchlists2025 Support & Resistance & Safe Entry Zone Tips - newser.com
Will Forte Biosciences Inc. stock gain from lower inflationJuly 2025 Intraday Action & AI Driven Stock Movement Reports - newser.com
What downside risks could hit Forte Biosciences Inc. (37T) stockLong Setup & Community Trade Idea Sharing - newser.com
Can Forte Biosciences Inc. (37T) stock deliver strong annual returnsJuly 2025 Setups & Low Risk Profit Maximizing Plans - newser.com
Is Forte Biosciences Inc. (37T) stock vulnerable to rate hikes2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Will Forte Biosciences Inc. (37T) stock profit from AI boomJuly 2025 Spike Watch & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-11-19 14:11:29 - newser.com
What drives Forte Biosciences Inc stock priceMid Cap Growth Trends & Budget Friendly Growth Tips - earlytimes.in
Why Forte Biosciences Inc. stock is in analyst buy zoneMarket Risk Summary & Technical Buy Zone Confirmations - newser.com
Developing predictive dashboards with Forte Biosciences Inc. data2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
Chardan Capital Reaffirms “Buy” Rating for Forte Biosciences (NASDAQ:FBRX) - Defense World
How analysts revise price targets for Forte Biosciences Inc. (37T) stock2025 Market Trends & Scalable Portfolio Growth Methods - newser.com
Why Forte Biosciences Inc. (37T) stock appeals to dividend investorsWatch List & Real-Time Volume Trigger Notifications - newser.com
Why Forte Biosciences Inc. stock appeals to analystsMarket Movement Recap & Reliable Breakout Forecasts - newser.com
Chardan Capital Maintains Forte Biosciences (FBRX) Buy Recommendation - Nasdaq
Chardan Capital Maintains Buy Rating for FBRX at $61 Target | FB - GuruFocus
Published on: 2025-11-17 02:42:28 - newser.com
Will Forte Biosciences Inc. stock outperform growth indexesEarnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):